Merus to Present at BofA Securities 2025 Health Care Conference

Rhea-AI Summary

Merus (Nasdaq: MRUS), a biotechnology company specializing in oncology and the development of multispecific antibodies (Biclonics® and Triclonics®), has announced its participation in the BofA Securities 2025 Health Care Conference. CEO Bill Lundberg will engage in a fireside chat on May 15, 2025, at 8:40 a.m. PT/11:40 a.m. ET. The presentation will be available via webcast on the company's Investors webpage, with a recording accessible for a limited time afterward.

News Market Reaction – MRUS

+8.47%

1 alert

+8.47% News Effect

On the day this news was published, MRUS gained 8.47%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics^® and Triclonics^®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT/11:40 a.m. ET.

The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus
Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics^®. Multiclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and LinkedIn.

Multiclonics^®, Biclonics^® and Triclonics^® are registered trademarks of Merus N.V.

Investor and Media Inquiries:
Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
s.spear@merus.nl

Kathleen Farren
Merus N.V.
Director IR/Corp Comms
617-230-4165
k.farren@merus.nl

FAQ

When is Merus (MRUS) presenting at the BofA Securities 2025 Health Care Conference?

Merus will present at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025, at 8:40 a.m. PT/11:40 a.m. ET.

Who will represent Merus (MRUS) at the BofA Securities 2025 Healthcare Conference?

Bill Lundberg, M.D., President and Chief Executive Officer of Merus, will represent the company in a fireside chat.

How can investors access Merus's (MRUS) presentation at the BofA Securities conference?

The presentation will be available via webcast on the Investors page of Merus's website, with an archived version accessible for a limited time after the event.

What type of antibody technology does Merus (MRUS) develop?

Merus develops innovative, full-length multispecific antibodies called Biclonics® and Triclonics® for oncology applications.